Delays At The Handoff: Where Breakdowns Occur Among The Sponsor, CRO, And Site

By Jason C. Bork, President and Founder, Pintail Solutions

Clinical trial delays are often discussed as if they begin and end at the site.

Sites are slow. Sites are unresponsive. Sites do not understand the urgency. Sites are the bottleneck.

Sometimes that is true. Often, it is not. At least, it is not the whole truth.

In many studies, the most significant delays begin earlier — at the handoff between the sponsor, CRO, site, and the growing number of vendors and third parties required to launch a modern trial. The breakdown is not always caused by lack of effort. It is usually caused by protocol burden, unclear ownership, disconnected communication, late budgets and contracts, unrealistic recruitment assumptions, and process expectations that do not match how work actually gets done.

The uncomfortable reality is that sponsors are often part of the delay. That can be hard to say out loud because the sponsor funds the work, sets the expectations, and holds the CRO accountable. But if we want trials to start faster, we have to be willing to examine the full system, including the sponsor’s role in creating friction.

The sponsor-CRO-site handoff is not a single event. It is a critical transition zone that gets revisited again and again throughout the life of a study. When it is managed well, sites understand the study, contracts and budgets are negotiated, systems are ready, the study team has a realistic path to activation, and recruiting goes as planned. When it is managed poorly, everyone begins working from different assumptions, and the trial loses weeks before the first patient is even consented.

This article identifies 10 of the most common points at which a trial can break down before and after patient recruitment.

Where The Handoff First Breaks Down

The initial breakdown is often isolated protocol development. Historically, many sponsors wrote protocols based on their most similar previous protocol, followed by a discussion about what else to add. That approach often created data-rich clinical trials, but it frequently came at the expense of tremendous patient and site burden. Just as importantly, it was often done without a clear understanding of how all the exploratory data would actually be used or whether it would be used at all.

Pharma and biotech companies have matured significantly in engaging patient feedback to optimize protocols for patient burden. It is sometimes debated how much that feedback is incorporated into the final approved protocol. However, site feedback and an understanding of site burden remain far behind.

Sites are on the front lines of clinical trial execution. They cannot be forgotten or ignored, and they largely do not appreciate only talking to the CRO. They crave sponsor engagement and want to share their insights on how to make the protocol more site friendly.

Why does this matter? Because protocol amendments kill studies. Lost momentum and progress are never fully regained.

Perhaps one of the best consulting outcomes we have had with a client was facilitating site discussions regarding the feasibility of trial operations. It was a difficult study. The sponsor walked away recognizing that the protocol would never be executed successfully because of site-level challenges. So, they regrouped and listened. Nobody wanted to delay that study or the work that followed, but the right decision was to start over.

Get the protocol right up front by balancing science, patient burden, and site experience, and the study has a much better chance of being completed as planned.

The Second Breakdown Happens At Start-Up

A start-up plan cannot be a high-level timeline that assumes everything will move in sequence. It needs to show the real work: site identification, feasibility, contracts, budgets, regulatory submissions, system access, vendor readiness, training, recruitment planning, monitoring expectations, and activation criteria.

Sponsors also need to configure it for and then communicate it to each site. For sites, knowing where to start is not always obvious. Sponsors and CROs can help by developing a process map that shows what needs to get done, what dependencies exist, and what order sites can expect the work to follow.

Sponsors must clearly communicate what sites can expect from them and from the CRO. When a RACI diagram, meaning Responsible, Accountable, Consulted, and Informed, is paired with the process map, everyone knows what to expect from each other and what role they play.

The Third Breakdown Is Communication

Too many study start-ups rely on mass emails, generic trackers, and long distribution lists. These tools create the appearance of communication without creating alignment. A mass email may technically inform the site, but if it doesn’t go to the right person or is only sent to the principal investigator, the meaning in the message can be lost.

A common example is sending operational start-up information to the PI. CROs have become efficient, so to speak, by sending mass emails to trial PIs and thus claiming effective communication. The PI is essential to the study, but the PI is not usually the person coordinating document collection, reviewing start-up logistics, scheduling internal reviews, or managing day-to-day activation steps.

In many cases, the clinical research coordinator or site operations lead is the person who needs the information first. When the wrong contact receives the right information, the start-up process stalls.

And while CROs are often responsible for site activations, sponsors should note the role they can play. Sites want to hear from sponsors. Sites love hearing from sponsors.

Sites often feel beat up or disparaged by the CRO, frequently because of poor communication and unclear ownership. But they feel like partners when engaging directly with the sponsor. Sponsors typically cannot be part of every conversation if they are working through a CRO, but a little goes a long way. A really long way.

Sites want to feel heard and to be part of the partnership. This enables long-term commitment and study prioritization at the site long after activation.

The Fourth Breakdown Is Budgets And Contracts

In most site start-ups, budgets and contracts are on the critical path. They are also predictably late. Everyone knows this, yet many teams treat them as if they will somehow move faster this time. They rarely do. In addition, many sites will not initiate study start-up until contracts and budgets are fully executed.

Budget and contract delays are not merely administrative. They affect site engagement, staffing decisions, recruitment planning, and trust. A site that waits weeks for a budget response begins to question whether the study is truly ready. A CRO that cannot get sponsor input on fallback positions cannot negotiate effectively. A sponsor that has not aligned internally on acceptable terms creates avoidable churn.

This is why budget and contract work should begin aggressively from the start. Sponsor and CRO teams should meet two to four times per month early in start-up and more frequently when negotiations are active or key sites are delayed.

These meetings should not merely be status updates. They should be decision meetings: What is stuck? Who owns the response? What fallback position is acceptable? What must be escalated today?

Getting to a 30-minute video or phone call sooner rather than later progresses everything faster.

The Fifth Breakdown Is Not Knowing Your Sites

CROs and sponsors do not know their sites. And I mean really know their sites.

We have done work for clients where we knew a site would be heads down for two weeks closing out another study. We knew they would make zero progress on our trial until that was done. But with trust and strong relationships, we also knew the site would prioritize our start-up over all their other work as soon as the closeout was complete.

We have done client work where we knew maternity leaves and vacation schedules for key site staff and could plan accordingly. We have uncovered that the user interface for vendor portals looked different for sites than it did for sponsors, meaning the help being provided was not actually helping because the sponsor did not know what the site was experiencing.

And if you really want to be a site hero: Know what you have already asked and validated at the site. Sites get asked the same questions for every trial. Site staff have been retrained on the same scales or assessments. Eliminate that redundancy, and you could become the sponsor or CRO of choice among sites, and it will positively affect your trial execution.

The Sixth Breakdown Is Not Knowing Your First Patient

The sixth breakdown is not knowing where your first trial participant is coming from.

Everyone is focused on study start-up, and once the study is activated, there is no celebration. CROs and sponsors immediately start asking why the site has not screened anyone yet. This has to be part of the integrated conversation during start-up.

CROs may change site contacts post-activation, and the new person may not have the start-up history or understand what the site has gone through. They may not know the current temperature of the relationship across sponsor, CRO, and site. New people come in with new metrics and more pressure.

Prior to site activation, all three (or more) parties must discuss who the first trial participant is, and the second, and the third.

Sites will often run a participant or two through the screening criteria to see what works and what doesn’t. It is better for everyone when this experience comes early. Get a few participants into the trial, understand the patient and site experience, understand how the other vendors work, and then gear up to truly recruit trial participants.

The Seventh Breakdown Is Recruitment Realism

Sponsors and CROs often build study assumptions around aggressive enrollment numbers that help win business or support optimistic timelines demanded by executive leadership. Sites may feel pressured to provide optimistic numbers to win the trial. Often, both sides are well-intentioned, but they fail to recognize the bigger picture. These numbers may look good in a proposal, but they can collapse quickly when tested against actual site capabilities.

Understanding where potential participants are going to come from is critical. Understanding how the CRO and site plan to bring them in is key.

Also note that many sites have a competitive edge. Regularly share with them the trial recruitment status, including screenings and randomizations. Challenge sites and bring out the best in them.

Another common misperception is that study monitors can help sites with recruitment. They cannot. Recruitment requires a different skillset. More importantly, it requires a very different site-CRO relationship. And that matters.

The Eighth Breakdown Is Personnel Turnover

Role changes occur frequently at the CRO and site level. You are not going to stop it, but you can plan for it.

As a sponsor, understand how you can quickly get CRO and site staff trained and productive for your study. Determine what is most important up front without overwhelming new staff. And recognize that this is the sponsor’s responsibility to ensure it gets done: Address turnover in your contracts, particularly with CROs. Consider percent turnover per year, expectations regarding clinical trial and therapeutic experience, transition timing, and related continuity requirements.

Turnover is going to happen. Plan accordingly. Document best practices. Know which CROs and sites minimize turnover or manage it better than others.

The Ninth Breakdown Is Failing To Monitor Along The Way

This breakdown seems to be mostly solved for trials today. However, even when monitoring occurs throughout the trial, the findings and learnings are often perceived as individual site findings or individual site learnings.

Rarely are monitoring findings integrated across sites.

Think about what can be uncovered when sponsors or CROs look at findings across 30, 300, or 1,200 sites versus looking at each site individually. Larger risks driven by protocol design or unclear communication can be alleviated. Sponsors and CROs can be proactive with sites about what to watch for or be careful of based on learnings from other sites.

This data is rarely used to enable trial delivery, and it is powerful. Be one of the first to solve this.

In addition, think through how AI is leveraged within monitoring and across the rest of the study. What models and learnings can you derive when monitoring findings are incorporated across the entire study and plugged into a system that can discern patterns better than you and I can?

The opportunity is very real.

The 10th Breakdown Is… Not Knowing Your Sites

Yes, we are repeating it. You cannot truly partner with a site unless you know where they are. And where they are will change throughout your trial because of professional and personal circumstances: key study closeouts, new study start-ups, competing trials, personnel transitions, weddings, funerals, childbirths, and more.

With one client, we were requesting additional resources to help a site recruit, and the site and CRO were confused.

“But that site is knocking it out of the park.”

Yes, we knew that. We also knew the site had run through all the potential participants in its database and would soon be recruiting from the wild. That is going to be different.

Sites largely know their patients. They have a feel for interest, eligibility, transportation, and retention. Recruiting from the wild is different. Earned media, paid media, social media, and community events all need to be coordinated, paid for, and delivered. The handoffs here are key to continued success.

A Checklist For Smoother Sponsor-CRO-Site Handoffs

Before site engagement begins, sponsors, CROs, and sites need to align on the following:

1. Assess the Protocol for Site Operational Readiness and Participant Burden

• Evaluate protocol complexity, patient burden, and site operational experience.
• Assess visit schedules, procedures, travel requirements, and consent burden.

2. Build a Complete Trial Road Map and Study Start-up Process Map

• Document the full path from protocol development to study closeout, with clear ownership and engagement through a RACI diagram.
• Define all start-up activities, owners, timelines, dependencies, and decision points.
• Establish escalation triggers for delayed or off-track activities.
• Align sponsors, CROs, sites, and vendors on the process before execution begins.

3. Define Governance, Ownership, and Decision Rights

• Assign ownership for every study activity.
• Define which decisions the CRO can make independently.
• Establish approval turnaround expectations.
• Create clear escalation pathways for unresolved issues.

4. Identify the Right Site Stakeholders

• Confirm primary operational contacts at each site.
• Identify regulatory, contract, budget, start-up, and recruitment contacts.
• Determine how and when to leverage direct sponsor engagement.
• Validate communication preferences and responsibilities.

5. Establish Communication and Escalation Practices

• Use direct conversations to resolve delays and misunderstandings promptly.
• Define escalation criteria before start-up and before recruitment begins.
• Hold focused meetings centered on decisions, blockers, risks, and next actions.

6. Create Contract and Budget Rules of Engagement

• Define negotiation boundaries, fallback language, and budget line items.
• Establish approval thresholds and turnaround expectations.
• Identify approvers and backup approvers.
• Hold recurring sponsor-CRO contract and budget review meetings.
• Track and escalate delayed negotiations with prompt video or phone calls involving all necessary parties.

7. Validate Recruitment and Site Feasibility Assumptions

• Distinguish realistic enrollment projections from aspirational goals.
• Verify recruitment sources and site capabilities.
• Assess competing studies and enrollment risks.
• Confirm operational feasibility before site selection.

8. Manage Vendors, CRO Performance, and Study Changes

• Identify all vendors and their responsibilities.
• Document vendor dependencies and risks.
• Monitor CRO staffing continuity and onboarding quality.
• Treat key staff turnover and protocol amendments as significant operational events requiring planning and retraining.

9. Maintain a Single Source of Truth

• Use one tracker or dashboard for start-up and one for recruitment.
• Monitor contracts, budgets, regulatory status, vendor readiness, training, systems access, recruitment readiness, monitoring readiness, and activation milestones.
• Ensure status reflects reality not assumptions.
• Provide visibility to sponsors, CROs, and key stakeholders.

10. Monitor Performance and Capture Lessons Learned

• Track recruitment, site engagement, protocol adherence, data quality, issue resolution, and CRO performance.
• Plan closeout activities early.
• Document lessons learned during start-up, execution, and closeout.
• Use findings to improve future studies and site activations.

The Leadership Difference              

Study execution improves when leaders start treating handoffs as operational risks and opportunities not just administrative tasks. The sponsor-CRO-site handoff is where strategy becomes execution. It is where timelines either become real or quickly erode.

Faster start-up and recruitment do not come from pushing sites harder or sending more emails. They come from clearer ownership, better communication, disciplined process management, integrated protocol design, realistic recruitment planning, and the willingness to address the issues teams often avoid.

That includes saying, when necessary, that the sponsor is contributing to the delay. It also includes saying when the CRO is under-engaged, when site communication is going to the wrong person, when budget decisions are too slow, when recruitment numbers are unrealistic, when the protocol is too burdensome, or when turnover has left the team untrained.

Clinical development is too expensive, too competitive, and too important to let preventable handoff failures consume weeks, months, or even years of a study timeline. The organizations that improve start-up and recruiting performance will be those that bring structure to the messy middle, hold all parties accountable, and create enough clarity for teams to move with confidence.

About The Author:

Jason C. Bork is a life sciences executive with more than 30 years of experience across large pharma, CRO, and startup organizations. He is an entrepreneur known for seeing the essence, distilling the complex into actionable steps, and developing those around him to new levels of fulfillment. From business strategy, organizational change, and operational excellence, Jason enables organizations to solve critical challenges, deliver high-impact projects, and move into the future with clarity and confidence. He has authored multiple scientific papers and book chapters and is a distinguished public speaker. Jason founded Pintail Solutions, a life sciences consulting organization, in 2015.